Nemolizumab improved itching and sleep for a year in young children. Can Galderma expand its FDA label?
Nemolizumab improved itching and sleep for a year in young children. Can Galderma expand its FDA label?
Pharma & Biotech
Pharma & Biotech
Galderma is paying $1.5bn for a $330m skincare business. What makes ZO Skin Health valuable?
Galderma has agreed to acquire ZO Skin Health from investors including Blackstone and the Obagi family for an enterprise value of $1.5 billion. The transaction adds approximately $330 million in annual sales and a network of more than 16,500 professional accounts, although near-term integration spending is expected to weigh on margins.
Pharma & Biotech
Could BBT001 quarterly dosing differentiate Bambusa in the atopic dermatitis biologics market?
Bambusa’s BBT001 produced an early atopic dermatitis signal, but larger trials must confirm safety, durability and quarterly dosing.
Pharma & Biotech
Why Galderma’s acne gel approval could quietly reset the over the counter dermatology market
Acne care is moving from prescription desks to retail shelves. Galderma’s Differin Epiduo switch tests how far OTC dermatology can go.
Pharma & Biotech
How Regenerating Skin Nectar with TriHex+ could strengthen Galderma’s aesthetics ecosystem
Galderma has launched Regenerating Skin Nectar with TriHex+. Read why this matters for peri-procedural skincare, clinics, and regenerative aesthetics.
Pharma & Biotech
Galderma backs new evidence for Sculptra and Restylane in fast-evolving patient demand segments
Read how Galderma’s new interim data could influence aesthetic treatment planning in menopause and GLP-1-related volume loss.
Pharma & Biotech
Why Galderma is turning ALASTIN into a clinic workflow strategy, not just a skincare brand
Galderma’s ALASTIN Signature Practices aim to embed skincare into aesthetic workflows. Read what this means for clinics, competition, and growth.
Pharma & Biotech
What Galderma’s nemolizumab phase II data mean for the competitive biologic landscape in pediatric eczema
Galderma's nemolizumab phase II data in children aged 2-11 show 52-week itch and lesion relief. Read the analysis.
Pharma & Biotech
How Galderma is repositioning Restylane Contour beyond cheeks into full-face structural correction
FDA approval of Restylane Contour for temple hollowing signals a shift in facial aesthetics. Discover what this means for the industry and future treatments.
Pharma & Biotech
How Galderma’s We Are All Sculptra program reframes collagen biostimulation in aesthetic medicine
Galderma launches a two-year Sculptra initiative tracking real-world outcomes. Discover what this means for regenerative aesthetics and durability claims.